The Adamas Pharmaceuticals, Inc. (ADMS) Receives Average Recommendation of “Buy” from Brokerages

The Adamas Pharmaceuticals, Inc. (ADMS) Receives Average Recommendation of “Buy” from Brokerages

Several research firms recently commented on ADMS. Cowen and Company reiterated an “outperform” rating and set a $45.00 target price on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Mizuho reiterated a “buy” rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. BidaskClub cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. Finally, Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd.

Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.50.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the business’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $17.05, for a total value of $5,967,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 731,041 shares of company stock worth $12,476,149 in the last three months. Insiders own 29.00% of the company’s stock.

Large investors have recently made changes to their positions in the stock. American International Group Inc. raised its stake in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the period. Wells Fargo & Company MN raised its stake in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the last quarter. Trexquant Investment LP purchased a new stake in Adamas Pharmaceuticals during the first quarter valued at $287,000. Russell Investments Group Ltd. purchased a new stake in Adamas Pharmaceuticals during the fourth quarter valued at $469,000. Finally, Goldman Sachs Group Inc. raised its stake in Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after buying an additional 41,436 shares during the last quarter. 71.37% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) remained flat at $17.17 during mid-day trading on Monday. 124,770 shares of the company were exchanged. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $19.50. The firm has a 50-day moving average of $17.39 and a 200 day moving average of $16.84. The stock’s market capitalization is $383.90 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 45.19%. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.47) EPS for the current fiscal year.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Related posts

Leave a Comment